Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

NASDAQ Market News

NEXT STORY
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
PREV STORY
Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ThromboGenics Business Update – H1 2017

Press release                                                          7 September, 2017Regulated Information Good Progress in Advancing Diabetic Eye Disease Portfolio ...

author_avatar
NASDAQ Market News

Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting

author_avatar
NASDAQ Market News

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder

author_avatar
NASDAQ Market News